|
|
||||||||
Review |
1 Laboratory of Cardiovascular Endocrinology and Department of Cardiovascular Medicine, Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, Pisa, Italy.
2 Scuola Superiore S. Anna, Pisa, Italy.
aAddress correspondence to this author at: Laboratory of Cardiovascular Endocrinology and Cell Biology, C.N.R. Institute of Clinical Physiology, Via Trieste 41, 56126 Pisa, Italy. Fax 39-0585-493601; e-mail clerico{at}ifc.cnr.it.
Background: We used evidence-based laboratory medicine principles to compare the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) assays for the diagnosis of heart failure.
Methods: In May 2006, we performed a computerized literature search of the online National Library of Medicine to select studies specifically designed to compare the diagnostic accuracy of BNP and NT-proBNP assays. The comparison took into account the area under the curve and diagnostic odds ratio (DOR) derived from ROC analysis of original studies.
Results: Both BNP and NT-proBNP assays were found to be clinically useful for the diagnosis of heart failure. Metaanalysis of these data was difficult because of the heterogeneity of data regarding patient population, diagnostic criteria, end-points, and immunoassay methods for both BNP and NT-proBNP. Separate metaanalyses were performed for acute and chronic heart failure. In chronic heart failure, the diagnostic DOR for BNP (8.44, 95% CI 4.6615.30) was not significantly different from that of NT-proBNP (23.36, 95% CI 9.3858.19). In patients with acute heart failure, the mean DOR for BNP (16.46, 95% CI 10.6525.43) was not significantly different from that of NT-proBNP (18.61, 95% CI 12.9926.65).
Conclusion: Our results indicate that both BNP and NT-proBNP assays have a high degree of diagnostic accuracy and clinical relevance for both acute and chronic heart failure.
The following articles in journals at HighWire Press have cited this article:
![]() |
S. Niizuma, Y. Iwanaga, T. Yahata, Y. Tamaki, Y. Goto, H. Nakahama, and S. Miyazaki Impact of Left Ventricular End-Diastolic Wall Stress on Plasma B-Type Natriuretic Peptide in Heart Failure with Chronic Kidney Disease and End-Stage Renal Disease Clin. Chem., July 1, 2009; 55(7): 1347 - 1353. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Vassalle and M. G. Andreassi Genetic Polymorphisms of the Natriuretic Peptide System in the Pathogenesis of Cardiovascular Disease: What Lies on the Horizon? Clin. Chem., May 1, 2009; 55(5): 878 - 887. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Emdin, S. Vittorini, C. Passino, and A. Clerico Old and new biomarkers of heart failure Eur J Heart Fail, April 1, 2009; 11(4): 331 - 335. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Niizuma, Y. Iwanaga, T. Yahata, Y. Goto, T. Kita, S. Miyazaki, and H. Nakahama Plasma B-type natriuretic peptide levels reflect the presence and severity of stable coronary artery disease in chronic haemodialysis patients Nephrol. Dial. Transplant., February 1, 2009; 24(2): 597 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Due-Andersen, U. Pedersen-Bjergaard, T. Hoi-Hansen, N. V. Olsen, C. Kistorp, J. Faber, F. Boomsma, and B. Thorsteinsson NT-pro-BNP during hypoglycemia and hypoxemia in normal subjects: impact of renin-angiotensin system activity J Appl Physiol, April 1, 2008; 104(4): 1080 - 1085. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Mueller Comparison of the Diagnostic Accuracy of BNP and NT-proBNP in Acute and Chronic Heart Failure Clin. Chem., September 1, 2007; 53(9): 1719 - 1720. [Full Text] [PDF] |
||||
![]() |
A. Clerico, M. Fontana, L. Zyw, C. Passino, and M. Emdin The authors of the article cited above respond: Clin. Chem., September 1, 2007; 53(9): 1720 - 1721. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |